查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2000459

太空生物学和多体学市场预测至2034年——按产品、组件、技术、体学类型、应用和地区分類的全球分析

Spatial Biology & Multi-Omics Market Forecasts to 2034 - Global Analysis By Product, By Component, By Technology, By Omics Type, By Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预计到 2026 年，全球空间生物学和多组体学市场将达到 3.3998 亿美元，并在预测期内以 10.6% 的复合年增长率增长，到 2034 年达到 8.4189 亿美元。

空间生物学和多组体学是指在保持生物分子（例如DNA、RNA、蛋白质和代谢物）在组织和细胞内空间排列不变的情况下，分析这些生物分子的综合技术。这些方法结合了基因组学、转录组学、蛋白质组学和代谢体学以及空间映射工具，以阐明复杂生物系统中分子相互作用的发生机制。这项技术有助于更深入地了解疾病机制、肿瘤微环境和细胞异质性。太空生物学和多体学平台正日益广泛地应用于精准医疗、生物标记发现和药物研发，帮助研究人员在自然生物学环境中可视化分子活性和相互作用。

精准医疗检测的需求日益增长

精准医疗致力于根据个体的基因、分子和细胞特征优化治疗方法。太空生物学技术使研究人员能够在组织的空间环境中研究基因表现和蛋白质-蛋白质相互作用。这使得科学家能够更深入地了解细胞层面的疾病机制。製药和生物技术公司正越来越多地利用这些技术来识别治疗标靶并开发个人化疗法。随着医疗保健转向更加以患者为中心的治疗策略转变，空间生物学和多体学技术的应用也不断增长。

复杂数据的分析与解释

复杂的数据技术会产生庞大且高度复杂的数据集，这些数据集融合了基因组、转录组、蛋白质组和空间资讯。解读这类多维资料需要先进的运算工具和专业知识。许多研究机构在有效整合和分析这些数据方面面临挑战。缺乏标准化的资料处理流程进一步加剧了这个过程的复杂性。因此，资料管理的复杂性可能会阻碍空间生物学和多体学平台的广泛应用。

肿瘤学和生物标记发现领域的拓展

在癌症研究中，了解肿瘤微环境和细胞异质性变得日益重要。太空生物学技术使研究人员能够分析癌细胞如何与周围组织和免疫细胞相互作用，从而为识别新的生物标记和治疗标靶提供宝贵的见解。多体学整合进一步增强了检测疾病特异性分子特征的能力。製药公司正积极投资这些技术，以改善癌症的诊断和治疗方法研发。随着肿瘤学研究在全球的扩展，对空间生物学解决方案的需求预计将会成长。

熟练的生物资讯专家短缺

处理多体学数据需要计算生物学、资料科学和高级统计分析的专业知识。然而，具备管理和解读这些复杂资料集所需技能的人才储备有限。这种人才短缺会减缓研究进展，并限制太空生物学技术的有效应用。许多机构在培训能够操作高阶分析工具的人员方面也面临挑战。如果没有足够的专业知识，这些技术的潜在优势可能无法充分发挥。

新冠疫情的影响：

新冠疫情对空间生物学和多组体学市场产生了重大影响。研究人员利用多组体学技术研究了SARS-CoV-2感染和免疫反应的分子机制。太空生物学工具帮助科学家了解病毒如何影响各种组织和细胞类型。这促使人们对先进的体学技术产生了更大的研究兴趣，并获得了更多资金支持。然而，疫情造成的干扰最初导致许多机构的实验室运作和研究活动延误。整体而言，疫情加速了先进生物分析技术在感染疾病研究的应用。

在预测期内，空间转录组学平台细分市场预计将成为最大的细分市场。

预计在预测期内，空间转录组学平台将占据最大的市场份额。这是因为这些平台能够对组织样本中的基因表现进行高解析度映射。研究人员可以在维持组织环境空间背景的同时，分析特定细胞中基因的表现。这种能力在研究癌症、神经系统疾病和发炎性疾病等复杂疾病方面尤其有用。製药公司和学术机构正在广泛利用空间转录组学进行生物标记发现和治疗标靶识别。此外，该技术还有助于与其他体学方法整合，从而获得更深入的生物学见解。

在预测期内，药物研发领域预计将呈现最高的复合年增长率。

在预测期内，药物发现领域预计将呈现最高的成长率，这主要得益于太空生物学和多体学技术在药物研发中日益广泛的应用。这些技术有助于阐明疾病机制、验证药物标靶，并更精准地检验治疗反应。整合多组体学资料能够帮助研究人员更深入了解疾病相关的复杂生物学路径。製药公司正越来越多地将空间分析融入其临床前和转化研究流程，这不仅提高了药物发现的效率，也降低了临床试验失败的风险。

市占率最大的地区：

在预测期内，北美预计将占据最大的市场份额，这主要得益于其强大的研究基础设施以及在生物技术和基因组学领域的大量投资。该地区汇聚了许多主要企业、製药公司和学术研究机构。政府资助和私人投资为基于体学的研究倡议提供了强有力的支持。此外，先进的定序技术和生物资讯学专业知识的普及正在加速太空生物学领域的创新。产业界和学术机构之间的许多合作也促进了技术进步。

复合年增长率最高的地区：

在预测期内，亚太地区预计将呈现最高的复合年增长率，这主要得益于生技产业的扩张和生命科学研究投资的增加。中国、日本、韩国和印度等国家正在加强其在基因组学和生物医学研究方面的能力。该地区各国政府正透过资助计画和创新倡议支持体学研究。製药和生物技术公司数量的不断增长也促进了先进研究技术的应用。此外，人们健康意识的提高和对精准医疗的需求也在加速市场成长。

免费客製化服务：

所有购买此报告的客户均可享受以下免费自订选项之一：

  • 企业概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域划分
    • 应客户要求，我们提供主要国家和地区的市场估算和预测，以及复合年增长率（註：需进行可行性检查）。
  • 竞争性标竿分析
    • 根据产品系列、地理覆盖范围和策略联盟对主要企业进行基准分析。

目录

第一章执行摘要

  • 市场概览及主要亮点
  • 驱动因素、挑战与机会
  • 竞争格局概述
  • 战略洞察与建议

第二章：研究框架

  • 研究目标和范围
  • 相关人员分析
  • 研究假设和限制
  • 调查方法

第三章 市场动态与趋势分析

  • 市场定义与结构
  • 主要市场驱动因素
  • 市场限制与挑战
  • 投资成长机会和重点领域
  • 产业威胁与风险评估
  • 技术与创新展望
  • 新兴市场/高成长市场
  • 监管和政策环境
  • 新冠疫情的影响及復苏前景

第四章：竞争环境与策略评估

  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争公司之间的竞争
  • 主要企业市占率分析
  • 产品基准评效和效能比较

第五章 全球空间生物学与多体学市场：依产品划分

  • 空间转录组学平台
  • 空间基因组系统
  • 空间蛋白质体学平台
  • 多体学整合平台
  • 其他产品

第六章 全球空间生物学与多体学市场：依组件划分

  • 装置
  • 试剂和试剂盒
  • 消耗品
  • 软体
  • 其他规则

第七章 全球空间生物学与多体学市场：依技术划分

  • 次世代定序
  • 原位杂合反应
  • 质谱成像
  • 多重萤光
  • 人工智慧与多体学的整合
  • 其他技术

第八章 全球空间生物学与多体学市场：按体学类型划分

  • 基因组学
  • 转录组学
  • 蛋白质体学
  • 代谢体学
  • 其他体学类型

第九章 全球空间生物学与多体学市场：按应用划分

  • 肿瘤学调查
  • 神经学检查
  • 免疫学调查
  • 药物发现
  • 生物标记发现
  • 其他用途

第十章 全球空间生物学与多体学市场：按地区划分

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 比利时
    • 瑞典
    • 瑞士
    • 波兰
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 马来西亚
    • 新加坡
    • 越南
    • 其他亚太国家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥伦比亚
    • 智利
    • 秘鲁
    • 其他南美国家
  • 世界其他地区（RoW）
    • 中东
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 以色列
      • 其他中东国家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲国家

第十一章 策略市场资讯

  • 工业价值网络和供应链评估
  • 空白区域和机会地图
  • 产品演进与市场生命週期分析
  • 通路、经销商和打入市场策略的评估

第十二章 产业趋势与策略倡议

  • 併购
  • 伙伴关係、联盟和合资企业
  • 新产品发布和认证
  • 扩大生产能力和投资
  • 其他策略倡议

第十三章：公司简介

  • 10x Genomics, Inc.
  • NanoString Technologies, Inc.
  • Illumina, Inc.
  • Akoya Biosciences, Inc.
  • Thermo Fisher Scientific Inc.
  • Bruker Corporation
  • Standard BioTools Inc.
  • BGI Genomics
  • Parse Biosciences
  • Lunaphore Technologies SA
  • Olink Holding AB
  • Oxford Nanopore Technologies plc
  • SciLifeLab
  • Visium Diagnostics
  • ImmunoGenomics, Inc.
Product Code: SMRC34505

According to Stratistics MRC, the Global Spatial Biology & Multi-Omics Market is accounted for $339.98 million in 2026 and is expected to reach $841.89 million by 2034 growing at a CAGR of 10.6% during the forecast period. Spatial Biology & Multi-Omics refers to integrated technologies that analyze biological molecules such as DNA, RNA, proteins, and metabolites-while preserving their spatial organization within tissues or cells. These approaches combine genomics, transcriptomics, proteomics, and metabolomics with spatial mapping tools to reveal how molecular interactions occur within complex biological systems. The technology enables deeper understanding of disease mechanisms, tumor microenvironments, and cellular heterogeneity. Spatial biology and multi-omics platforms are increasingly used in precision medicine, biomarker discovery, and drug development, helping researchers visualize molecular activity and interactions within their natural biological context.

Market Dynamics:

Driver:

Growing demand for precision medicine research

Precision medicine focuses on tailoring treatments based on an individual's genetic, molecular, and cellular characteristics. Spatial biology technologies allow researchers to study gene expression and protein interactions within the spatial context of tissues. This helps scientists better understand disease mechanisms at a cellular level. Pharmaceutical and biotechnology companies are increasingly using these technologies to identify therapeutic targets and develop personalized therapies. As healthcare shifts toward more patient-specific treatment strategies, the adoption of spatial biology and multi-omics technologies continues to rise.

Restraint:

Complex data analysis and interpretation

Complex data technologies generate massive and highly complex datasets that combine genomic, transcriptomic, proteomic, and spatial information. Interpreting such multidimensional data requires advanced computational tools and specialized expertise. Many research institutions face challenges in integrating and analyzing this data effectively. The lack of standardized data processing pipelines further complicates the process. As a result, the complexity of data management can limit the widespread adoption of spatial biology and multi-omics platforms.

Opportunity:

Expansion in oncology and biomarker discovery

Cancer research increasingly relies on understanding tumor microenvironments and cellular heterogeneity. Spatial biology technologies enable researchers to analyze how cancer cells interact with surrounding tissues and immune cells. This provides valuable insights for identifying novel biomarkers and therapeutic targets. Multi-omics integration further enhances the ability to detect disease-specific molecular signatures. Pharmaceutical companies are actively investing in these technologies to improve cancer diagnosis and treatment development. As oncology research expands globally, demand for spatial biology solutions is expected to increase.

Threat:

Limited skilled bioinformatics professionals

Handling multi-omics data requires expertise in computational biology, data science, and advanced statistical analysis. However, there is a limited workforce with the necessary skills to manage and interpret these complex datasets. This shortage can slow research progress and limit the effective use of spatial biology technologies. Many organizations also face challenges in training personnel to operate sophisticated analytical tools. Without adequate expertise, the potential benefits of these technologies may not be fully realized.

Covid-19 Impact:

The COVID-19 pandemic had a notable impact on the Spatial Biology & Multi-Omics market. Researchers used multi-omics technologies to study the molecular mechanisms of SARS-CoV-2 infection and immune responses. Spatial biology tools helped scientists understand how the virus affected different tissues and cell types. This increased research interest and funding for advanced omics technologies. However, pandemic-related disruptions initially slowed laboratory operations and research activities in many institutions. Overall, the pandemic accelerated the adoption of advanced biological analysis technologies in infectious disease research.

The spatial transcriptomics platforms segment is expected to be the largest during the forecast period

The spatial transcriptomics platforms segment is expected to account for the largest market share during the forecast period as these platforms enable high-resolution mapping of gene expression within tissue samples. Researchers can analyze how genes are expressed in specific cells while preserving the spatial context of the tissue environment. This capability is particularly valuable in studying complex diseases such as cancer, neurological disorders, and inflammatory conditions. Pharmaceutical companies and academic institutions widely use spatial transcriptomics for biomarker discovery and therapeutic target identification. The technology also supports integration with other omics approaches for deeper biological insights.

The drug development segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the drug development segment is predicted to witness the highest growth rate due to increasing use of spatial biology and multi-omics technologies in pharmaceutical research. These technologies help identify disease mechanisms, validate drug targets, and monitor therapeutic responses more accurately. Integrating multi-omics data allows researchers to better understand complex biological pathways involved in diseases. Pharmaceutical companies are increasingly incorporating spatial analysis into preclinical and translational research workflows. This improves the efficiency of drug discovery and reduces the risk of clinical trial failures.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to strong research infrastructure and high investments in biotechnology and genomics. The region hosts many leading biotechnology companies, pharmaceutical firms, and academic research institutions. Government funding and private investments strongly support omics-based research initiatives. Additionally, the presence of advanced sequencing technologies and bioinformatics expertise accelerates innovation in spatial biology. Numerous collaborations between industry and academic organizations also contribute to technological advancements.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by expanding biotechnology industries and increasing investments in life science research. Countries such as China, Japan, South Korea, and India are strengthening their genomic and biomedical research capabilities. Governments across the region are supporting omics research through funding programs and innovation initiatives. The rising number of pharmaceutical and biotechnology companies is also contributing to the adoption of advanced research technologies. Additionally, growing healthcare awareness and demand for precision medicine are accelerating market growth.

Key players in the market

Some of the key players in Spatial Biology & Multi-Omics Market include 10x Genomics, Inc., NanoString Technologies, Inc., Illumina, Inc., Akoya Biosciences, Inc., Thermo Fisher Scientific Inc., Bruker Corporation, Standard BioTools Inc., BGI Genomics, Parse Biosciences, Lunaphore Technologies SA, Olink Holding AB, Oxford Nanopore Technologies plc, SciLifeLab, Visium Diagnostics and ImmunoGenomics, Inc.

Key Developments:

In January 2026, 10x Genomics entered a strategic collaboration with CareDx to launch ImmuneScape, a multiomics research initiative. The program will use 10x's Xenium spatial and Chromium Flex single cell platforms to create high-resolution maps of immune mechanisms in transplant rejection, aiming to advance personalized transplant medicine.

In May 2024, Bruker Corporation completed its acquisition of NanoString Technologies for $392.6 million in cash, buying the assets and rights associated with the company after NanoString filed for bankruptcy . This strategic acquisition was aimed at bolstering Bruker's portfolio in the rapidly growing spatial biology market by integrating NanoString's CosMx and GeoMx spatial platforms.

Products Covered:

  • Spatial Transcriptomics Platforms
  • Spatial Genomics Systems
  • Spatial Proteomics Platforms
  • Multi-Omics Integration Platforms
  • Other Products

Components Covered:

  • Instruments
  • Reagents & Kits
  • Consumables
  • Software
  • Other Components

Technologies Covered:

  • Next-Generation Sequencing
  • In Situ Hybridization
  • Mass Spectrometry Imaging
  • Multiplexed Immunofluorescence
  • AI & Multi-Omics Integration
  • Other Technologies

Omic Types Covered:

  • Genomics
  • Transcriptomics
  • Proteomics
  • Metabolomics
  • Other Omic Types

Applications Covered:

  • Oncology Research
  • Neurology Research
  • Immunology Research
  • Drug Development
  • Biomarker Discovery
  • Other Applications

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Spatial Biology & Multi-Omics Market, By Product

  • 5.1 Spatial Transcriptomics Platforms
  • 5.2 Spatial Genomics Systems
  • 5.3 Spatial Proteomics Platforms
  • 5.4 Multi-Omics Integration Platforms
  • 5.5 Other Products

6 Global Spatial Biology & Multi-Omics Market, By Component

  • 6.1 Instruments
  • 6.2 Reagents & Kits
  • 6.3 Consumables
  • 6.4 Software
  • 6.5 Other Components

7 Global Spatial Biology & Multi-Omics Market, By Technology

  • 7.1 Next-Generation Sequencing
  • 7.2 In Situ Hybridization
  • 7.3 Mass Spectrometry Imaging
  • 7.4 Multiplexed Immunofluorescence
  • 7.5 AI & Multi-Omics Integration
  • 7.6 Other Technologies

8 Global Spatial Biology & Multi-Omics Market, By Omics Type

  • 8.1 Genomics
  • 8.2 Transcriptomics
  • 8.3 Proteomics
  • 8.4 Metabolomics
  • 8.5 Other Omics Types

9 Global Spatial Biology & Multi-Omics Market, By Application

  • 9.1 Oncology Research
  • 9.2 Neurology Research
  • 9.3 Immunology Research
  • 9.4 Drug Development
  • 9.5 Biomarker Discovery
  • 9.6 Other Applications

10 Global Spatial Biology & Multi-Omics Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 10x Genomics, Inc.
  • 13.2 NanoString Technologies, Inc.
  • 13.3 Illumina, Inc.
  • 13.4 Akoya Biosciences, Inc.
  • 13.5 Thermo Fisher Scientific Inc.
  • 13.6 Bruker Corporation
  • 13.7 Standard BioTools Inc.
  • 13.8 BGI Genomics
  • 13.9 Parse Biosciences
  • 13.10 Lunaphore Technologies SA
  • 13.11 Olink Holding AB
  • 13.12 Oxford Nanopore Technologies plc
  • 13.13 SciLifeLab
  • 13.14 Visium Diagnostics
  • 13.15 ImmunoGenomics, Inc.

List of Tables

  • Table 1 Global Spatial Biology & Multi-Omics Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Spatial Biology & Multi-Omics Market, By Product (2023-2034) ($MN)
  • Table 3 Global Spatial Biology & Multi-Omics Market, By Spatial Transcriptomics Platforms (2023-2034) ($MN)
  • Table 4 Global Spatial Biology & Multi-Omics Market, By Spatial Genomics Systems (2023-2034) ($MN)
  • Table 5 Global Spatial Biology & Multi-Omics Market, By Spatial Proteomics Platforms (2023-2034) ($MN)
  • Table 6 Global Spatial Biology & Multi-Omics Market, By Multi-Omics Integration Platforms (2023-2034) ($MN)
  • Table 7 Global Spatial Biology & Multi-Omics Market, By Other Products (2023-2034) ($MN)
  • Table 8 Global Spatial Biology & Multi-Omics Market, By Component (2023-2034) ($MN)
  • Table 9 Global Spatial Biology & Multi-Omics Market, By Instruments (2023-2034) ($MN)
  • Table 10 Global Spatial Biology & Multi-Omics Market, By Reagents & Kits (2023-2034) ($MN)
  • Table 11 Global Spatial Biology & Multi-Omics Market, By Consumables (2023-2034) ($MN)
  • Table 12 Global Spatial Biology & Multi-Omics Market, By Software (2023-2034) ($MN)
  • Table 13 Global Spatial Biology & Multi-Omics Market, By Other Components (2023-2034) ($MN)
  • Table 14 Global Spatial Biology & Multi-Omics Market, By Technology (2023-2034) ($MN)
  • Table 15 Global Spatial Biology & Multi-Omics Market, By Next-Generation Sequencing (2023-2034) ($MN)
  • Table 16 Global Spatial Biology & Multi-Omics Market, By In Situ Hybridization (2023-2034) ($MN)
  • Table 17 Global Spatial Biology & Multi-Omics Market, By Mass Spectrometry Imaging (2023-2034) ($MN)
  • Table 18 Global Spatial Biology & Multi-Omics Market, By Multiplexed Immunofluorescence (2023-2034) ($MN)
  • Table 19 Global Spatial Biology & Multi-Omics Market, By AI & Multi-Omics Integration (2023-2034) ($MN)
  • Table 20 Global Spatial Biology & Multi-Omics Market, By Other Technologies (2023-2034) ($MN)
  • Table 21 Global Spatial Biology & Multi-Omics Market, By Omics Type (2023-2034) ($MN)
  • Table 22 Global Spatial Biology & Multi-Omics Market, By Genomics (2023-2034) ($MN)
  • Table 23 Global Spatial Biology & Multi-Omics Market, By Transcriptomics (2023-2034) ($MN)
  • Table 24 Global Spatial Biology & Multi-Omics Market, By Proteomics (2023-2034) ($MN)
  • Table 25 Global Spatial Biology & Multi-Omics Market, By Metabolomics (2023-2034) ($MN)
  • Table 26 Global Spatial Biology & Multi-Omics Market, By Other Omics Types (2023-2034) ($MN)
  • Table 27 Global Spatial Biology & Multi-Omics Market, By Application (2023-2034) ($MN)
  • Table 28 Global Spatial Biology & Multi-Omics Market, By Oncology Research (2023-2034) ($MN)
  • Table 29 Global Spatial Biology & Multi-Omics Market, By Neurology Research (2023-2034) ($MN)
  • Table 30 Global Spatial Biology & Multi-Omics Market, By Immunology Research (2023-2034) ($MN)
  • Table 31 Global Spatial Biology & Multi-Omics Market, By Drug Development (2023-2034) ($MN)
  • Table 32 Global Spatial Biology & Multi-Omics Market, By Biomarker Discovery (2023-2034) ($MN)
  • Table 33 Global Spatial Biology & Multi-Omics Market, By Other Applications (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.